Share price more than doubled
Chart courtesy of stockchartsShares of EPCT rose more than 73% " WOW " closing at 3.95 after the company said that a compound it licensed to Myriad Genetics Inc. shows potential as a tumor-destroying drug. The drug, Azixa, acted as a vascular disrupting agent in a study on the primary and secondary treatment of brain tumors. The drug in effect deprives blood from the tumor and kills it. Myriad is currently conducting two Phase II clinical trials on the drug. The impact of this news in stock price was immediate as show the chart.
Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations.The charts provided here are not meant for investment purposes and only serve as technical examples.
Labels: EPCT
